Abstract：
Each year the European Association of Urology (EAU) produce a document based on the most recent evidence on the diagnosis, therapy, and follow-up of testicular cancer (TC).
To represent a summarised version of the EAU guidelines on TC for 2023 with a focus on key changes in the 2023 update.
A multidisciplinary panel of TC experts, comprising urologists, medical and radiation oncologists, and pathologists, reviewed the results from a structured literature search to compile the guidelines document. Each recommendation in the guidelines was assigned a strength rating.
For the 2023 EAU guidelines on TC, a review and restructure were undertaken. The key changes incorporated in the 2023 update include: new supporting text regarding venous thromboembolism prophylaxis in males with metastatic germ cell tumours receiving chemotherapy; quality of life after treatment; an update of the histological classifications and inclusion of the World Health Organization 2022 pathological classification; inclusion of the revalidation of the 1997 International Germ Cell Cancer Collaborative Group prognostic risk factors; and a new section covering oncology treatment protocols.
The 2023 version of the EAU guidelines on TC include the highest available scientific evidence to standardise the management of TC. Better stratification and optimisation of treatment modalities will continue to improve the high survival rates for patients with TC.
This article presents a summary of the European Association of Urology guidelines on testicular cancer published in 2023 and includes the latest recommendations for management of this disease. The guidelines are a valuable resource that may help patients in understanding treatment recommendations.
To represent a summarised version of the EAU guidelines on TC for 2023 with a focus on key changes in the 2023 update.
A multidisciplinary panel of TC experts, comprising urologists, medical and radiation oncologists, and pathologists, reviewed the results from a structured literature search to compile the guidelines document. Each recommendation in the guidelines was assigned a strength rating.
For the 2023 EAU guidelines on TC, a review and restructure were undertaken. The key changes incorporated in the 2023 update include: new supporting text regarding venous thromboembolism prophylaxis in males with metastatic germ cell tumours receiving chemotherapy; quality of life after treatment; an update of the histological classifications and inclusion of the World Health Organization 2022 pathological classification; inclusion of the revalidation of the 1997 International Germ Cell Cancer Collaborative Group prognostic risk factors; and a new section covering oncology treatment protocols.
The 2023 version of the EAU guidelines on TC include the highest available scientific evidence to standardise the management of TC. Better stratification and optimisation of treatment modalities will continue to improve the high survival rates for patients with TC.
This article presents a summary of the European Association of Urology guidelines on testicular cancer published in 2023 and includes the latest recommendations for management of this disease. The guidelines are a valuable resource that may help patients in understanding treatment recommendations.
摘要：
背景：欧洲泌尿外科协会（EAU）每年都会根据诊断的最新证据产生一份文件，治疗,以及睾丸癌（TC）的随访。
目标：代表2023年关于TC的EAU指南的摘要版本，重点是2023年更新的关键变化。
方法：由TC专家组成的多学科小组，包括泌尿科医生，医学和放射肿瘤学家，和病理学家，回顾了结构化文献检索的结果，以编制指南文件。指南中的每个建议都被分配了强度等级。
结果：对于2023年EAU关于TC的指南，进行了审查和重组。2023年更新中纳入的主要变化包括：有关接受化疗的转移性生殖细胞肿瘤男性静脉血栓栓塞预防的新支持文本；治疗后的生活质量；组织学分类的更新和世界卫生组织2022病理分类的纳入；包括对1997年国际生殖细胞癌协作组预后风险因素的重新验证；以及涵盖肿瘤治疗方案的新部分。
结论：关于TC的EAU指南的2023版包含了标准化TC管理的最高可用科学证据。更好的分层和优化治疗方式将继续提高TC患者的高生存率。
结果：本文总结了2023年发表的欧洲泌尿外科协会关于睾丸癌的指南，并包括了该疾病的最新治疗建议。该指南是一种宝贵的资源，可以帮助患者理解治疗建议。
目标：代表2023年关于TC的EAU指南的摘要版本，重点是2023年更新的关键变化。
方法：由TC专家组成的多学科小组，包括泌尿科医生，医学和放射肿瘤学家，和病理学家，回顾了结构化文献检索的结果，以编制指南文件。指南中的每个建议都被分配了强度等级。
结果：对于2023年EAU关于TC的指南，进行了审查和重组。2023年更新中纳入的主要变化包括：有关接受化疗的转移性生殖细胞肿瘤男性静脉血栓栓塞预防的新支持文本；治疗后的生活质量；组织学分类的更新和世界卫生组织2022病理分类的纳入；包括对1997年国际生殖细胞癌协作组预后风险因素的重新验证；以及涵盖肿瘤治疗方案的新部分。
结论：关于TC的EAU指南的2023版包含了标准化TC管理的最高可用科学证据。更好的分层和优化治疗方式将继续提高TC患者的高生存率。
结果：本文总结了2023年发表的欧洲泌尿外科协会关于睾丸癌的指南，并包括了该疾病的最新治疗建议。该指南是一种宝贵的资源，可以帮助患者理解治疗建议。
